Related Experiment Video
Updated: Dec 26, 2025
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
720
[Biologicals and small molecules for rheumatoid arthritis]
1Klinik für Innere Medizin III/Abteilung für Rheumatologie, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090, Wien, Österreich. stephan.blueml@meduniwien.ac.at.
Zeitschrift Fur Rheumatologie
|March 18, 2020
Summary
Recent advancements in rheumatoid arthritis treatment include targeted synthetic and biological disease-modifying antirheumatic drugs (DMARDs). While many patients achieve remission, further improvements are needed for non-responders.
Area of Science:
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) management has significantly advanced with new drug classes.
- Conventional disease-modifying antirheumatic drugs (DMARDs) lack known molecular targets.
Purpose of the Study:
- To provide an overview of current effective therapies for rheumatoid arthritis.
- To highlight the progress in RA treatment, including novel drug classes.
Main Methods:
- Review of currently available and effective substances for RA treatment.
- Discussion of biological (bDMARDs) and targeted synthetic (tsDMARDs) drugs.
Main Results:
- New drugs, including bDMARDs and tsDMARDs, offer targeted mechanisms of action.
- These therapies have enabled remission induction for a substantial number of RA patients.
- A significant proportion of patients still exhibit inadequate response to existing treatments.
Conclusions:
- The therapeutic landscape for rheumatoid arthritis has been transformed by targeted therapies.
- While remission is achievable for many, unmet needs persist for non-responders.
- Ongoing research and development are crucial for further improving RA management.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
389
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
389
01:28Drug Products: Biologics, Biosimilars and Interchangeables
184
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
184
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
399
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
399
01:29Inflammatory Bowel Disease IV: Pharmacological Management
385
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
385
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
356
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
356
01:20The JAK-STAT Signaling Pathway
11.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.6K